Resverlogix's Success in Inflammation Program Results in 2 Pat... ( Novel small molecules illustrate po...)

Resverlogix's Success in Inflammation Program Results in 2 Patents Filed

Date:5/19/2009

    Novel small molecules illustrate potential cost effective approach for
    rheumatoid arthritis

    TSX Exchange Symbol: RVX

CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases. Two new patent applications have been filed for novel compounds and their use in regulating inflammatory markers. Inflammatory markers are proteins generated by the body during periods of inflammation. These patents were filed based on the successful results demonstrated in numerous preclinical studies across several disease areas. The particular results achieved in the collagen induced arthritis (CIA) model in rats demonstrated that Resverlogix's proprietary molecules markedly reduced inflammation while improving mobility of arthritic animals.

"Resverlogix's R&D program has made significant strides this past year," said Donald J. McCaffrey, President & CEO of Resverlogix. "The Company has identified several molecules that have the potential for disease modifying effects in inflammatory disorders such as rheumatoid arthritis. Resverlogix's R&D team is continuing to examine the various disease indications in inflammation which would have the greatest potential impact for both patients and payer groups," continued McCaffrey.

A significant unmet medical need exists for safe, effective and economical therapies for specific inflammation markets. For example, a small molecular drug for rheumatoid arthritis is estimated to range in price from US $180 - US $6000 per person per annum. A biologic, or large molecule drug, can cost in the order of US $13,000 - US $30,000 per patient per annum. In 2007, the global market for rheumatoid arthritis alone was estimated to be in excess of US $11 billion a year and is expected to
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
2. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
3. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
8. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
9. Addiction Treatment Finds Success Treating Brain Deficiencies through the Belly
10. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
11. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery

Post Your Comments:

Resverlogix's Success in Inflammation Program Results in 2 Pat...( Novel small molecules illustrate po...)